Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

被引:170
作者
Faber, MS [1 ]
Fuhr, U [1 ]
机构
[1] Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany
关键词
D O I
10.1016/j.clpt.2004.04.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective: Cytochrome P450 (CYP) 1A2 activity is induced by cigarette smoking. Thus smoking cessation in patients while they are undergoing therapy with a CYP1A2 substrate such as theophylline or clozapine increases its concentrations and may cause adverse effects. Our objective was to determine the time course of CYP1A2 activity changes after smoking cessation in heavy smokers as the basis for dosing adaptation schemes. Methods: The study was conducted in 8 men and 4 women (all white) who smoked 20 cigarettes or more per day. Sudden smoking cessation was carried out after a 14-day run-in period. Subjects were phenotyped for CYP1A2 activity at 6, 4, and I day before smoking cessation and at 0, 1, 2, 3, 6, 8, 10, and 13 days thereafter by use of the paraxanthine-to-caffeine ratio in plasma 6 hours after a 148-mg caffeine test dose. A monoexponential decay of CYP1A2 activity to a residual value was fitted to the data by nonlinear regression analysis. Results: On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P < .01), by 36.1% (30.9%-42.2%), from 2.47 mL (.) min(-1) (.) kg(-1) body weight (2.03-3.00 mL (.) min(-1) (.) kg(-1) body weight) to a new steady state of 1.53 mL (.) min(-1) (.) kg(-1) body weight (1.24-1.89 mL (.) min(-1) (.) kg(-1) body weight). The apparent half-life of CYP1A2 activity decrease was 38.6 hours (27.4-54.4 hours). Conclusion: Doses of CYP1A2 substrates with a narrow therapeutic range should be decreased immediately on cessation of heavy smoking. As a rule of thumb, a stepwise daily dose reduction of approximately 10% until the fourth day after smoking cessation is proposed, which should be accompanied by therapeutic drug monitoring.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 32 条
  • [1] BALOGH A, 1992, INT J CLIN PHARM TH, V30, P383
  • [2] Very nigh cytochrome P4501A2 activity and nonresponse to clozapine
    Bender, S
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 1998, 55 (11) : 1048 - 1050
  • [3] CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST
    BERTILSSON, L
    CARRILLO, JA
    DAHL, ML
    LLERENA, A
    ALM, C
    BONDESSON, U
    LINDSTROM, L
    DELARUBIA, IR
    RAMOS, S
    BENITEZ, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) : 471 - 473
  • [4] Smoking impact on CYP1A2 activity in a group of patients with schizophrenia
    Bozikas, VP
    Papakosta, M
    Niopas, L
    Karavatos, A
    Mirtsou-Fidani, V
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (01) : 39 - 44
  • [5] Pharmacokinetics of clozapine and risperidone: A review of recent literature
    Byerly, MJ
    DeVane, CL
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (02) : 177 - 187
  • [6] MULTIPLE-DOSE PHARMACOKINETICS OF CLOZAPINE IN PATIENTS
    CHOC, MG
    LEHR, RG
    HSUAN, F
    HONIGFELD, G
    SMITH, HT
    BORISON, R
    VOLAVKA, J
    [J]. PHARMACEUTICAL RESEARCH, 1987, 4 (05) : 402 - 405
  • [7] Optimal dosing of atypical antipsychotics in adults: A review of the current evidence.
    Citrome, L
    Volavka, J
    [J]. HARVARD REVIEW OF PSYCHIATRY, 2002, 10 (05) : 280 - 291
  • [8] CLOZAPINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, AND THERAPEUTIC USE IN SCHIZOPHRENIA
    FITTON, A
    HEEL, RC
    [J]. DRUGS, 1990, 40 (05) : 727 - 747
  • [9] BIOTRANSFORMATION OF CAFFEINE AND THEOPHYLLINE IN MAMMALIAN-CELL LINES GENETICALLY ENGINEERED FOR EXPRESSION OF SINGLE CYTOCHROME-P450 ISOFORMS
    FUHR, U
    DOEHMER, J
    BATTULA, N
    WOLFEL, C
    KUDLA, C
    KEITA, Y
    STAIB, AH
    [J]. BIOCHEMICAL PHARMACOLOGY, 1992, 43 (02) : 225 - 235
  • [10] Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations
    Fuhr, U
    Rost, KL
    Engelhardt, R
    Sachs, M
    Liermann, D
    Belloc, C
    Beaune, P
    Janezic, S
    Grant, D
    Meyer, UA
    Staib, AH
    [J]. PHARMACOGENETICS, 1996, 6 (02): : 159 - 176